Entecavir with or without peginterferon for children with hepatitis B
Treatments studied
Part of Digestive system, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 6 years old.
- You must have chronic hepatitis B (tested positive for HBsAg and HBeAg for at least 6 months).
- Your viral load must be very high (over 10 million copies per mL).
- Your liver function tests (ALT) must be normal, and an ultrasound of your liver must be normal.
- You must not have had any previous hepatitis B treatment.
- You must not have other infections or serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a second medicine to the standard hepatitis B treatment helps young children clear the virus better. It may help improve liver health and reduce long-term risks.
This study looks at how well antiviral medicines work in children with chronic hepatitis B. It may help doctors find better ways to treat children who are starting treatment or who have been on treatment for a while.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
Hear when a new Hepatitis B Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.